Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises € 8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders

Ghent, Belgium: 15 October 2018 - Sequana Medical NV, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicentre of the Flanders healthcare hub, and the investment of € 8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders.

More info on Sequana's website.


Next > Nexstim secures Business Finland funding for the development of wireless EMG devices

Previous > Varian Expands cancer care portfolio with Noona Healthcare acquisition